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IntroductIon
Pancreatic ductal adenocarcinoma (PDAC) is usually detected 
too late for curative treatment, and in 80% of patients surgical 
resection is not possible at the time of diagnosis [1]. Of those who 
undergo surgery and adjuvant chemotherapy, only 20–30% can 
expect to survive 5 years [2–4]. The best survival can be achieved 
if tumours are small at the time of resection, but such tumours are 
rarely found [5]. Ideally, pre-cancerous lesions could be removed 
before they progress. PDAC is generally accepted to arise from 
pancreatic intraepithelial neoplasms (PanINs), and these micro-
scopic lesions are graded from 1 to 3, with 3 being equivalent to 
carcinoma in situ. However, even PanIN3 are difficult or impos-
sible to identify by imaging. Intraductal papillary mucinous neo-
plasms (IPMNs) can be detected by pancreatic imaging. There 
is some controversy over whether IPMNs develop into PDAC, 
with invasive IPMN being a separate form of malignancy with a 
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Objectives: Intraductal papillary mucinous neoplasms (IPMNs) are associated with risk of pancreatic ductal 
adenocarcinoma (PDAC). It is unclear if an IPMN in individuals at high risk of PDAC should be 
considered as a positive screening result or as an incidental finding. Stratified familial pancreatic 
cancer (FPC) populations were used to determine if IPMN risk is linked to familial risk of PDAC.
MethOds: This is a cohort study of 321 individuals from 258 kindreds suspected of being FPC and undergoing 
secondary screening for PDAC through the European Registry of Hereditary Pancreatitis and Familial 
Pancreatic Cancer (EUROPAC). Computerised tomography, endoscopic ultrasound of the pancreas and 
magnetic resonance imaging were used. The risk of being a carrier of a dominant mutation predisposing 
to pancreatic cancer was stratified into three even categories (low, medium and high) based on: 
Mendelian probability, the number of PDAC cases and the number of people at risk in a kindred.
Results: There was a median (interquartile range (IQR)) follow-up of 2 (0–5) years and a median (IQR) 
number of investigations per participant of 4 (2–6). One PDAC, two low-grade neuroendocrine 
tumours and 41 cystic lesions were identified, including 23 IPMN (22 branch-duct (BD)). The PDAC 
case occurred in the top 10% of risk, and the BD-IPMN cases were evenly distributed amongst risk 
categories: low (6/107), medium (10/107) and high (6/107) (P = 0.63).
cOnclusiOns: The risk of finding BD-IPMN was independent of genetic predisposition and so they should be 
managed according to guidelines for incidental finding of IPMN.
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better prognosis [6]. PDAC do develop in patients with IPMN, 
sometimes after the IPMNs have been successfully resected [7], 
suggesting association of IPMN and cancer that goes beyond sim-
ple progression. Branch-duct (BD) IPMNs are found in at least 
5% of the general population and lead to invasive cancer in a very 
small proportion of cases [8]; this risk is very much higher in 
main-duct (MD) IPMNs [9]. Mixed-type IPMNs carry a similar 
risk of invasive carcinoma as MD-IPMN (around 45%) [10].
Guidelines on management of IPMNs were produced in Sen-
dai in 2006, with refinement in the Fukuoka guidelines (2012 and 
2016), in essence suggesting surveillance of BD-IPMN and pos-
sible resection of MD-IPMN. The American Gastroenterological 
Association introduced guidelines to limit the length of surveil-
lance of BD-IPMN; this remains controversial but enforces the 
idea of BD-IPMN as lesions that can usually be safely left in situ. 
A European guideline document has also been published, again 
recommending a conservative approach to managing BD-IPMN, 
but of not stratifying the risk of progression according to (amongst 
other factors) familial history of pancreatic cancer [11]. Screening 
for pancreatic cancer requires a highly enriched population with 
a high prevalence of PDAC; at present, the only accepted screen-
ing populations are those with autosomal dominant predisposition 
for pancreatic cancer [12]. Identifying a BD-IPMN during screen-
ing raises the question of whether the lesion should be managed 
according to standard guidelines or whether this represents a 
consequence of the genetic predisposition for cancer and so could 
merit immediate resection.
The International Cancer of the Pancreas Screening (CAPS) 
consortium has defined potentially relevant findings in screening 
as early PDAC (T1 N0 M0 R0), grade 3 PanIN, and high grade 
BD or MD IPMN [13]. We have reviewed 21 screening reports 
[14–34]; in total, 30 pancreatic cancers and 2 pancreatic neu-
roendocrine tumours were reported. However, the most common 
positive findings were cystic lesions, including 6 MD-IPMNs and 
60 BD-IPMNs. Of the 1780 individuals who were screened, 131 
underwent surgical resection due to what was considered to be a 
positive finding.
The European Registry of Hereditary Pancreatitis and Famil-
ial Pancreatic Cancer (EUROPAC) was established in 1997. 
EUROPAC recruits families with either hereditary pancreatitis or 
familial pancreatic cancer (FPC) and offers cancer screening on a 
research basis. This work only deals with screening in FPC. In the 
majority of FPC families no known causative mutation has been 
identified and DNA sequencing cannot be used to distinguish fam-
ilies with genuine autosomal dominant predisposition from fami-
lies where the cancer cluster occurs by chance or due to a polygenic 
predisposition. Estimates of relative risk of PDAC vary between 6- 
and 120-fold depending on the nature of family selection [35, 36], 
the 120-fold level being most consistent with autosomal dominant 
predisposition and lower values perhaps indicating a higher pro-
portion of random clusters which will not give adequate elevated 
prospective risk for screening.
This paper describes the results from EUROPAC pilot screening 
study. A PDAC case and an MD-IPMN were identified along with 
two low-grade neuroendocrine tumours, but the most frequent 
findings were cystic lesions, the most common of which were 
BD-IPMNs. If BD-IPMNs can genuinely be considered a positive 
finding in screening, then it would be logical to assume that they 
should be more frequently encountered in individuals with the 
highest risk of pancreatic cancer as a result of autosomal domi-
nant predisposition. We have assessed if familial risk (as opposed 
to risk due to other factors such as age or smoking) correlates with 
a higher incidence of IPMNs in our FPC kindreds.
MAterIALS And MethodS
Patients and ethics
EUROPAC is administered from Liverpool in the United King-
dom, Greifswald in Germany and Clichy in France, mainly 
recruiting from Western Europe. It is a patient-led registry (ethi-
cal approvals MREC 03/8/069 and 07/H1211/96). Screening 
inclusion depended on at least two first-degree relatives with con-
firmed PDAC or a high-risk mutation. In some of the EUROPAC 
families, a known causative mutation has been identified (muta-
tions in BRCA2, CDKN2a, STK11 or mismatch repair genes). 
These are associated with autosomal dominant predisposition 
that can be confirmed by segregation of the mutation with can-
cer cases. However, in most of our families DNA sequencing has 
not been possible in enough cases to confirm segregation, so we 
cannot rule out low penetrance in some of our families despite 
the presence of known causative mutations in screened indi-
viduals (e.g., a BRCA2 mutation cannot be guaranteed to equate 
to very high risk because the individual may have a protective 
genetic background not seen in high-risk families with BRCA2). 
All screened individuals had to be aged over 40 years or 10 years 
younger than the youngest affected first-degree relative.
Epidemiological data were collected via questionnaires sup-
ported by clinical consultations and stored on a database (Prog-
eny version 8.01) in accordance with the UK Data Protection Act 
(1998). Matched DNA was kept under the care of the Merseyside 
and Cheshire Genetics Service. Recruitment for screening was 
patient led, with approximately 40% uptake.
Screening protocol
Baseline measurements of serum glucose and Ca19-9 were per-
formed alongside imaging (both pancreas protocol computed 
tomography and endoscopic ultrasound of the pancreas). The 
screening process is summarised in Fig. 1. Consenting individu-
als had collection of duodenal juice, with secretin stimulation. If 
the juice contained no cancer-associated genetic abnormalities, 
participants entered a 3-yearly screening cycle, with staggered 
endoscopic ultrasound (EUS) and/or magnetic resonance imag-
ing. In patients without juice collection or with cancer-associated 
mutations in their juice, there was an annual pathway consisting 
of repeat blood testing and EUS. Abnormalities were discussed 
at the supra-regional pancreatic multi-disciplinary team meeting.
Molecular analysis of duodenal juice
Extracted DNA from juice was quantified by real-time PCR for a 
specific genomic DNA sequence (KRAS). The methodology for 
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molecular analysis has been previously described [37]: a yeast 
functional assay was used to identify p53 mutations, Amplifi-
cation Refractory Mutation System was employed for analysis 
of KRAS mutations and a real-time methylation-specific PCR 
assay for CDKN2a promoter methylation. For later analysis, deep 
sequencing of Tp53 was carried out on juice samples using an Ion 
Torrent Personal Genome Machine. Libraries were constructed 
as described in manufacturer's protocols [38], and in order to 
avoid false positive results from PCR error, the template DNA 
was diluted to 10 genomes per reaction prior to making each 
library. Minimum allele frequency for a genuine mutation would 
therefore be approximately 10, and a 1% mutation rate would be 
1 out of 10 libraries from the same patient with a mutant allele 
frequency of 10% and the rest wild type.
Risk calculation
The purpose of this study was to evaluate the relationship between 
screening results and familial predisposition, and risk was there-
fore only evaluated in terms of family structure. Other factors, 
such as age and smoking that increase risk of cancer but may also 
increase risk of cystic lesions, were not included. The concept of 
family index (FI) was used, whereby the number of cases of PDAC 
in each family was taken as the numerator and the square root of 
the number of at risk individuals as the denominator. To allow for 
no individuals of 40 or above, one was added to the number at risk.
=
√ ≥ +
.FI Number of affected individuals
[(Number of individuals in kindred 40 years) (1)]
Mendelian principles were used to calculate the chance of inher-
iting a high-risk allele. For example, any first-degree relative of a 
pancreatic cancer case has a 50% chance of being a mutation car-
rier, reducing to 25% in a nephew or niece. If a potential causative 
mutation was identified the chance was considered as 100%. FI was 
multiplied by percentage chance of inheritance to give an arbitrary 
score for risk (e.g., an individual in a family with FI = 0.5 and a 
50% chance of being a carrier has a risk score of 25).
The arbitrary risk score calculated was compared in prospective 
cancer cases on the registry to a division of families based simply 
on number of cases and number of generations affected.
Statistical analysis
Continuous variables are presented as median with interquartile 
range (IQR). Risk groups were created pragmatically based on 
tertiles of the whole screened population, giving low, medium 
and high risk. The numbers of each finding in each tertile were 
compared using Pearson's chi square or Fisher’s exact testing as 
appropriate.
reSuLtS
The demographics of all individuals consented and recruited to 
the FPC EUROPAC registry are described in Table 1. The families 
are split according to number of pancreatic cancer cases and gen-
erations affected.
In Table 2 all families that would have included individuals (reg-
istered or unregistered relatives) eligible for screening in the year 
2000 are shown, broken down by family type as in Table 1. The 
number of prospective cancers (i.e., cancers occurring after 2000 
Baseline
Ca 19-9 and fasting glucose
CT pancreas
Endoscopic ultrasound pancreas
Year 1+
Ca 19-9 and fasting glucose
EUS pancreas ± molecular analysis of pancreatic juice
MRI pancreas
MDT
‘3 hits’
Mt p53, Mt K-Ras, high p16
Annual screening
‘≤2 hits’
3 yearly screening
EUS & molecular analysis of pancreatic juice
Fig. 1 euROPAc screening protocol. there is a 3-yearly screening cycle following a baseline assessment consisting of computed tomography (ct), endo-
scopic ultrasound (eus) and blood tests. there is eus imaging at the end of each cycle, followed by collection of pancreatic juice (previously this was done 
by cannulation of the pancreatic duct, currently by collection from the duodenum following secretin stimulation) and molecular analysis the year after. in 
patients who do not have juice collection or who had a cancer-associated mutation in their duodenal juice, there is an annual pathway consisting of repeat 
blood testing and eus/magnetic resonance imaging (MRi). Any abnormalities identified in imaging or molecular tests are discussed at the supra-regional 
pancreatic multi-disciplinary team (Mdt) meeting. the Mdt may recommend further clinical investigations, surgery or whether the participant undergoes 
annual surveillance or regular clinical review and/or follow-up
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and before October 2016) is given, confirming the high risk of can-
cer in this cohort.
The prospective cancer cases are described in Table 3. There was 
a trend for the prospective cases to have slightly older age of cancer 
onset than the historical cases and this trend was seen in all cat-
egories of family. The median arbitrary risk score for all prospec-
tive cancer cases was 40, with the highest values in families with 
more cases of cancer (e.g., 3 cases in more than one generation 
having a median risk score of 50). Seventy-five percent of prospec-
tive pancreatic cancer cases had an arbitrary risk score at diagnosis 
of greater than 31.
Figure 1 shows the EUROPAC protocol for screening members 
of FPC kindreds. As of October 2016, there were 3031 individuals 
who would be eligible for secondary screening; however, only 791 
of these were registered. These 791 patients were informed of their 
eligibility and from this point onwards, uptake of screening was 
entirely patient led. The team did not approach patients beyond 
informing them of their eligibility for screening.
Table 1 Demographics of EUROPAC-registered individuals and the cancer cases in their families in October 2016 for comparison with the 
screened cohort
Family type Total 
kindreds
Total number of 
PDAC in kindreds
Registered individuals Number of indi-
viduals screened
Total registered  
Individuals
Current age range/ 
median
Gender Smoking
FPc ≥3 cases  
multi-generations
145 504 308 24–99/ 58 F = 195 
M = 113
Yes = 41 
no = 145 
ex = 94 
unknown = 28
84 individuals 
60 Families
FPc 2 cases  
2 generations
281 562 438 24–91/56 F = 275 
M = 163
Yes = 43 
no = 211 
ex = 135 
unknown = 49
130 individuals 
106 Families
FPc ≥3 cases  
1 generation
25 80 44 32–85/57 F = 27 
M = 17
Yes = 7 
no = 13 
ex = 14 
unknown = 10
6 individuals 
6 Families
FPc 2 cases  
1 generation
110 220 190 25–91/57 F = 130 
M = 60
Yes = 26 
no = 97 
ex = 56 
unknown = 11
48 individuals 
40 Families
BRCA2 mutation 54 39 81 28–84/57 F = 58 
M = 23
Yes = 4 
no = 37 
ex = 32 
unknown = 8
22 individuals 
20 Families
FAMMM 14 24 27 34–67/49 F = 19 
M = 8
Yes = 7 
no = 15 
ex = 4 
unknown = 1
9 individualsa 
8 Families
Pjs 6 2 7 19–69/44 F = 2 
M = 5
Yes = 1 
no = 3 
ex = 2 
unknown = 1
4 individuals 
4 Families
hnPcc 15 21 20 41–76/60 F = 12 
M = 8
Yes = 0 
no = 9 
ex = 7 
unknown = 4
8 individualsb 
5 Families
Otherc 66 83 84 30–92/59 F = 55 
M = 29
Yes = 8 
no = 43 
ex = 22 
unknown = 11
10 individuals 
9 Families
total 716 1535 1199 19–99/57 F = 773 
M = 426
Yes = 137 
no = 573 
ex = 366 
unknown = 123
321 individuals 
258 Families
EUROPAC european Registry of hereditary Pancreatitis and Familial Pancreatic cancer, F female, FAMMM familial atypical multiple mole melanoma, FPC familial pancre-
atic cancer, HNPCC hereditary non-polyposis colorectal cancer (lynch syndrome), M male, PDAC pancreatic ductal adenocarcinoma, PJS Peutz jegher’s syndrome
aFour individuals were recruited for screening from a family with a cdKn2a mutation but were later found to not be carriers
bFour individuals with Mlh1 mutations and 4 defined on family history alone
cFamilies with cancer syndromes (none with known causative mutations)
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EUROPAC had recruited 321 individuals for screening from 
cancer families up to October 2016 (321/3031 10.6% of all eligible 
individuals). In all, 123 participants had completed more than two 
screening cycles, 46 had completed two cycles, 71 one cycle and 11 
had a finding on baseline screening investigations, giving a total of 
786 screening cycles completed. In addition, there were 70 indi-
Table 2 Individuals in EUROPAC kindreds followed from 2000 to 2016 showing prospective cancers to demonstrate high risk
All individuals (registered or unregistered relative) Just pancreatic cancer cases New cancer 
cases 
2000–2016Total 
Individuals 
(kindreds)
Age (median 
& IQR)
Gender  
M=male 
F=female
Smoking Total 
cancer 
events
Age  
(median 
& IQR)
Gender M=Male 
F=Female
Smoking
Multi-
generation 
≥3 cases
1044 (44) 49 (29–64) 
N = 747
M = 532 
F = 512
Yes = 32 
no = 61 
ex = 33 
child = 93 
unknown = 825
158 61 
(54–68) 
N = 140
M = 83  
F = 75
Yes = 12 
no = 13 
ex = 4 
child = 0 
unknown = 129
23
two gen-
erations 2 
cases
1942 
(109)
44 
(24–62) 
N = 1356
M = 961 
F = 981
Yes = 50 
no = 96 
ex = 60 
child = 224 
unknown = 1512
218 64 
(56–72) 
N = 204
M = 96  
F = 122
Yes = 16 
no = 16 
ex = 5 
child = 0 
unknown = 181
30
single 
generation 
≥3 cases
553 
(15)
53 
(33–69) 
N = 248
M = 277 
F = 276
Yes = 3 
no = 5 
ex = 5 
child = 21 
unknown = 519
52 65 
(58–71) 
N = 47
M = 26  
F = 26
Yes = 1 
no = 0 
ex = 0 
child = 0 
unknown = 51
5
single 
generation 
2 cases
1201 
(57)
51 
(34–67) 
N = 748
M = 574 
F = 627
Yes = 25 
no = 42 
ex = 32 
child = 68 
unknown = 1034
115 64 
(56–72) 
N = 104
M = 52  
F = 63
Yes = 7 
no = 2 
ex = 4 
child = 0 
unknown = 102
20
EUROPAC european Registry of hereditary Pancreatitis and Familial Pancreatic cancer, IQR interquartile range
Table 3 Prospective cancer cases between 2000 and 2016 showing the range of familial risk
New cancer cases (2000–2016) Median FI at 
diagnosis (IQR)
Median risk score at 
diagnosis (IQR)
Total cancer 
events
Age (median  
& IQR)
Gender  
M=male F=female
Smoking
Multi-generation 
≥3 cases
23 73 
(60–80) 
N = 23
M = 11 
F = 12
Yes = 13 
no = 6 
ex = 3 
unknown = 1
1.0 (0.9–1.3) 50.0 (43.3–75.3)
two generations 
2 cases
30 68 
(61–74) 
N = 30
M = 20 
F = 10
Yes = 23 
no = 1 
ex = 3 
unknown = 3
0.7 (0.6–0.8) 33.3 (28.9–41.8)
single generation 
≥3 cases
5 68 
(57–80) 
N = 5
M = 2 
F = 3
Yes = 3 
no = 1 
ex = 1unknown = 0
1.0 (0.8–1.4) 48.5 (41.0–69.7)
single generation 
2 cases
20 68 
(57–80) 
N = 20
M = 8 
F = 12
Yes = 13 
no = 4 
ex = 3 
unknown = 0
0.7 (0.6–0.8) 37.8 (32.0–40.8)
total 78 68 
(60–75) 
N = 78
M = 41 
F = 37
Yes = 52 
no = 12 
ex = 10 
unknown = 4
0.8 (0.6–1.0) 40.0 (31.6–50.0)
FI family index, IQR interquartile range
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viduals who had been recruited and undergone baseline screening 
but with less than 1 year of follow-up and with no abnormal find-
ings. The median screening follow-up was 2 years (IQR 0–5) and 
the median number of screening investigations per participant was 
4 (IQR 2–6).
The findings from screening are summarised in Table  4 and 
Fig. 2. The most common findings were cystic lesions: 41 cystic 
lesions were identified, of which 1 was a main-duct IPMN and 22 
were branch-duct IPMNs. The other cystic lesions were too small 
for definitive radiological classification; although these may have 
been very small branch-duct IPMN, it does rule out larger lesions 
such as mucinous cystic neoplasias. Two pancreatic neuroendo-
crine tumours (pNETs) were discovered, both were resected and 
were found to be well differentiated. One PDAC was identified. 
In addition, a gastrointestinal stromal tumour was discovered 
in the stomach of one patient. Three pancreatic resections were 
performed: for both pNETs and for the MD-IPMN. Histological 
examination of the specimen from the MD-IPMN revealed low-
grade dysplasia of main lesion and also revealed an incidental 
branch-duct IPMN with low-grade dysplasia. The one PDAC case 
identified was unfortunately advanced at the time of diagnosis and 
was therefore inoperable. Within the screening cohort, there were 
four deaths from all causes; one being the advanced PDAC, two 
from extra-pancreatic malignancy and one cardiac-related death.
The most frequently used screening modality was EUS. Com-
puted tomography (CT) scan was only performed as part of 
baseline investigation, unless clinically indicated due to positive 
findings in other modalities. Magnetic resonance imaging (MRI) 
was only routinely introduced into the screening protocol from 
2014.
Of the 35 screened individuals with a known causative muta-
tion, only 2 had a significant finding on screening; 1 out of 22 with 
a BRCA2 mutation had a 10 mm BD-IPMN that regressed during 
clinical follow-up, and 1 out of 5 individuals with a CDKN2a muta-
tion had an 11 mm BD-IPMN which has remained stable after 36 
months of follow-up.
Only 48 participants consented for endoscopic retrograde chol-
angiopancreatography with molecular analysis of pancreatic juice 
and only 4 patients had positive molecular test results in at least 
two analyses. This is too small a group to make any significant 
conclusions. Two of these patients had cystic lesions that were 
too small for further characterisation. Both of the remaining par-
ticipants with two positive tests had EUS findings consistent with 
minimal change chronic pancreatitis (although neither had symp-
toms or diagnosis of pancreatitis and the imaging abnormalities 
resolved). The single PDAC case and one of the pNETs did not 
undergo pancreatic juice molecular analysis. The other pNET had 
undergone two separate pancreatic juice collections. The first gave 
wild-type KRAS and normal levels of CDKN2a promoter meth-
ylation (0.01%), and Tp53 analysis failed. The second test gave 
wild-type KRAS and Tp53, with CDKN2a analysis failing. The 
MD-IPMN case did not undergo pancreatic juice analysis in the 
screening cycle where the lesion was identified, and in a previous 
analysis they had wild-type KRAS and Tp53 with normal CDKN2a 
promoter methylation (0.018%).
In Fig. 2 each screening event is shown with the outcome colour 
coded, red for the cancer, pink for the pNETs, amber for the main-
duct IPMN, green for no significant finding, etc. The participants 
are ranked according to the risk score of the individual at the time 
of screening estimated as above. Four individuals were included for 
screening because of family history, but were found not to have the 
disease mutation (a CDKN2a mutation) identified subsequently 
in this family, and they therefore were classified as having a zero 
elevated risk. The PDAC case was identified in an individual who 
at the time of screening had 5 cases of PDAC in the family and 17 
individuals in the family tree over the age of 40 years, giving an FI 
of 1.179. There was a 50% chance of the individual being a carrier 
Table 4 Screening events stratified by risk group
Low risk Medium risk High risk
Median age (iQR): whole 
group
58 (47–65) 52 (46–61) 53 (48–63)
smoking: whole group
 Yes 5 (4.7%) 11 (10.3%) 5 (4.7%)
 no 56 (52.3%) 60 (56.1%) 65 (60.7%)
 ex 46 (43.0%) 36 (33.6%) 37 (34.6%)
 PdAc 0 0 1
 pnet 1 1 0
 Md-iPMn 0 1 0
 bd-iPMn 6 10 6
size of bd-iPMn
 3–5 mm 3 7 4
 6–10 mm 1 3 2
 >10 mm 2 0 0
Progression of bd-iPMn
 Progressed 2 1 0
 stable 3 7 4
 Regressed 1 2 2
 Other cystic lesions 5 6 7
  Median age (iQR): 
individuals with cystic 
lesions
60 (54–65) 52 (48–70) 59 (47–67)
smoking: cystic lesion group
 Yes 1 (9.1%) 2 (11.8%) 0
 no 6 (54.5%) 9 (52.9%) 7 (53.8%)
 ex 4 (36.4%) 6 (35.3%) 6 (46.2%)
  total findings (total 
follow-up years)
12 (260 
screening 
follow-up 
years)
18 (289 
screening 
follow-up 
years)
14 (239 
screening 
follow-up 
years)
 Finding/follow-up year 0.05 0.06 0.06
BD branch duct, IQR interquartile range, IPMN intraductal papillary mucinous 
neoplasm, MD main duct, PDAC pancreatic ductal adenocarcinoma, pNET 
pancreatic neuroendocrine tumour
P
a
n
c
r
e
a
s
 a
n
d
 B
il
ia
r
y
 T
r
a
c
T
7identification of cystic lesions by secondary screening...
© 2018 The Author(s) The American Journal of GastroenteroloGy
and so the risk score was 58.95. This put the individual’s familial 
risk in the top 10% of risk scores in the screened population.
Splitting the screening participants evenly into three groups 
(low, medium and high) as shown in Fig. 2 indicated no correlation 
between risk and incidence for branch-duct IPMN (χ2 = 0.937; 
P = 0.632).
dIScuSSIon
The screening described here was carried out under the assump-
tion of autosomal dominant predisposition for PDAC. Multigenic 
cancer predisposition will give heterogeneous risk with only par-
ticular combinations of alleles passing a threshold that would allow 
predictable development of malignancy, even if all family mem-
bers have some small elevated risk [39]. The combination of alleles 
responsible for specific cancer cases will be unlikely to be seen again 
in the same family, so prospective risk would be too low to justify 
cancer screening. Effective screening requires a single mutant gene 
that confers the bulk of risk, although this may well be context spe-
cific (some genetic backgrounds giving high penetrance and some 
low penetrance); in such a situation family members who are non-
carriers must be assumed not to be at any elevated risk.
The probability of a cluster of PDAC without such predispo-
sition will increase with the number of at-risk individuals in a 
kindred and will reduce with the number of pancreatic cancer 
cases. Risk for an individual will depend on their age, exposure to 
environmental risk factors and lifestyle, but none of these factors, 
alone or in combination, would merit inclusion of an individual in 
a screening programme, nor would they influence the prospective 
risk of other family members.
A screening finding must therefore be judged according to the 
genetic risk of an individual. The one case of PDAC occurred 
within the top 10% of familial risk and the one case of MD-IPMN 
was identified in a medium risk family. Twenty-two branch-duct 
IPMNs were identified with equal probability in individuals of all 
familial risk categories.
The 5-year follow-up of 367 individuals from the population-
based Study of Health in Pomerania (SHIP) identified 48 partici-
pants who developed cystic lesions (12.9%). Although the SHIP 
study is not directly comparable with the prospective screening 
described here, it is notable that we identified a total of 41 cystic 
lesions in our population of 321 participants (12.8%), and hence 
our data are entirely consistent with the expected discovery of 
cystic lesions in the general population [40]. Age is a risk factor 
both for the development of pancreatic cancer and IPMN (as shown 
in the SHIP analysis), and we deliberately did not include age in 
our risk model, as the question was whether genetic predisposi-
tion increased the risk of cystic lesions. Our hypothesis was that 
the cystic lesions were intermediates in a genetic predisposition for 
pancreatic cancer and could therefore be taken as a positive result 
in a cancer screen. The cystic lesions within the EUROPAC screen-
ing cohort were more common in older participants, but this was 
true even for the low-risk group, although very few prospective 
cancers occur in this group of patients (see Table 3) and presum-
ably many of the individuals in this group were at no greater risk 
of pancreatic cancer than any other individual of a similar age. The 
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Fig. 2 screening results stratified by risk that an individual carries a high penetrance mutation predisposing to pancreatic cancer. Risk was estimated 
based on number of cases of cancer, number of at-risk individuals in each family and the chance that a participant was carrying an autosomal dominant 
determinant of cancer predisposition. each individual is then represented by a coloured bar indicating the outcome of screening (as shown in the key). 
Positive events are indicated with arrows and the tertiles of risk (along with the 10% upper risk group) are indicated by boxes below the x-axis
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BD-IPMNs were also no larger or more likely to progress in the 
high-risk group than in the low-risk group.
There is little doubt that BD-IPMNs are associated with can-
cer risk. However, although an individual with a BD-IPMN may 
be at greater risk of cancer, our data suggest individuals with a 
higher inherited risk of PDAC are not at a higher risk of develop-
ing BD-IPMN. Previously, Capurso et al. [41] showed that IPMNs 
were more frequent in individuals with a familly history of pan-
creatic cancer, and this was based on 21 IPMN cases (5.4 %) with 
a first-degree family history of PDAC compared to 6 controls 
(1.6 %), but only 1 of these would have fitted the criteria for FPC 
and this patient still only had 1 first-degree relative with PDAC 
(plus 2 second-degree relatives). Our findings indicate that FPC 
is not associated with greater predisposition for IPMN; genetic 
predisposition for IPMN may well be associated with higher risk 
of PDAC. Similarly, patients who smoke or who have diabetes 
may well be more likely to develop IPMN and be more likely to 
develop cancer.
The link between genetic predispostion to cancer and to precur-
sor lesions is complex, and syndromes such as familial adenoma-
tous polyposis predispose to cancer because they predispose to 
precursor lesions. These precursor lesions, albeit more commonly 
found, are not greatly more prone to progression than similar 
lesions found in individuals without genetic predisposition for 
cancer [42]. In contrast, Lynch Syndrome (or hereditary non-
polyposis colorectal cancer (HNPCC)) increases the risk of pre-
cursor lesions progressing [43], and hence lesions are less likely to 
be found but are much more worrisome if identified. Naturally, if 
lesions are not related to the genetic predisposition for cancer then 
they will neither be more frequent nor more aggressive. There is 
emerging support for an alternative to the traditional progression 
model. A catastrophic process of cancer development associated 
with Acinar Ductal Metaplasia and lobular atrophy, independ-
ent of PanIN [44, 45], fits with observations in familial pancreatic 
cancer [46]. Atypical flat lesions may be positive screening results 
on the basis that they are the pre-cancerous lesion typical for FPC 
[47], but unfortunately, these cannot be identified without first 
resecting the pancreas.
Thus, the EUROPAC study does not support the inclusion of 
non-malignant pancreatic cystic lesions, including branch-duct 
IPMNs, as positive findings on screening individuals from FPC 
families.
The screening results presented here are consistent with the out-
comes described by other groups, with discovery of cystic lesions 
far outweighing identification of PDAC [14–34]. The poor return 
of screening programmes can be explained by inclusion of too 
many low-risk individuals in the screening cohorts. Any individ-
ual’s chance of being at high risk will be the same as the chance 
of carrying a predisposing mutation (e.g., 50% for a first-degree 
relative). The actual risk will be lower because superimposed is the 
chance that the family may just represent a random cluster of cases. 
This means that most individuals undergoing screening for PDAC 
on the sole basis of family history of the disease have no elevated 
risk. No elevated risk of PDAC means no elevated risk of precursor 
lesions.
In 2007, Wang et al. [39] developed the PancPro Mendelian 
model to identify high-risk individuals within FPC kindreds. In 
our report we used a much simpler (pragmatic) risk score based 
on the number of cases of pancreatic cancer in the family, which is 
the most widely recognised measure of familial risk [35], with the 
added advantage of stratifying risk within groups of families with 
equal numbers of pancreatic cancer cases (see Table 3). Although 
Table 3 shows that the prospective cancer cases have a higher FI 
than equivalent individuals in our screened cohort, who have not 
so far developed cancer, this cannot be considered as validation of 
FI as a concept as in order to do this we would have to show greater 
risk of cancer in a prospective cohort of individuals with standardi-
sation for all other risk factors (smoking, age, diabetes etc.). We are 
carrying out such a prospective analysis with the families shown 
in Table 1, but these data will not be available for some years. This 
arbitrary risk score, although inferior to PancPro in accuracy for 
quantifying PDAC risk, has the advantage for our purpose that it 
avoids factors that would apply to sporadic pancreatic cancer and 
cystic lesions, such as age and smoking. Independence of such risk 
factors was essential in showing that the familial predisposition 
for cancer was largely (or entirely) independent of risk of develop-
ing BD-IPMN. The prospective reporting of new cases of PDAC 
in individuals at higher familial risk than those being screened 
indicates the need for a strategy to encourage more high-risk indi-
viduals to participate in screening. By restricting screening using 
PancPro (or equivalent) it should be possible to focus resources on 
encouraging higher risk individuals to participate.
If we had identified an increased frequency of IPMN in higher-
risk individuals, we could have reasonably concluded that FPC 
predisposes to the development of IPMN which in turn predis-
poses to PDAC, but this was not the case. If we had found that 
IPMNs encountered during screening progressed to PDAC, we 
could have reasonably concluded that FPC increases the probabil-
ity of an IPMN progressing, but again this was not the case. We 
cannot conclude from this work that IPMNs are an intermediate 
stage in the development of PDAC within FPC kindreds. IPMNs 
identified during screening should on this basis be treated in the 
same way as IPMNs discovered incidentally in the general popula-
tion (according to the appropriate guidelines). A desirable feature 
of risk stratification is that it is unlikely to increase the yield of 
branch-duct IPMNs.
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Study Highlights
wHAT IS CURRENT kNOwLEDGE
✓there are families with multiple cases of pancreatic cancer 
suggesting autosomal dominant predisposition (true FPc).
✓clusters of pancreatic cancer cases will occur by chance 
giving little prospective increased cancer risk.
✓Screening of pancreatic cancer families frequently yields 
pancreatic cystic lesions but not many cancers.
✓Some sporadic pancreatic cystic lesions lead to cancer but 
most remain indolent.
✓It is unknown whether FPc influences either the incidence 
or progression of cystic lesions.
wHAT IS NEw HERE
✓Stratification by family history makes no difference to yield 
of cystic lesions within FPc kindreds.
✓Bd-IPMns may be incidental and so cannot be taken as a 
positive screening outcome.
✓Bd-IPMns found during screening should be managed in 
the same way as those found incidentally.
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